HR 5629 · in committee · significant
To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
Show full title
To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
- healthcare
What this bill does
- This bill cancels a 2024 HHS rule that relaxed requirements for opioid addiction medications like methadone and buprenorphine.
- It affects patients in opioid treatment programs who would lose access to take-home doses, telehealth evaluations, and streamlined admission.
- The rule changes take effect immediately upon the bill's passage with no implementation costs.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would restricting take-home doses and telehealth access to opioid medications affect treatment completion rates in rural or underserved communities?
- 02
What evidence supports the claim that the 2024 HHS rule's relaxed requirements led to problems serious enough to warrant reversing patient access improvements?
- 03
Which groups—patients, treatment providers, or public health officials—would bear the most burden if these medication access restrictions are reinstated?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-IN-9
Erin Houchin
Citizen cosponsors
0
In Congress
0/ 435
House Reps cosponsoring
Introduced 2025-09-30
Legislative timeline
2025-09-30 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-09-30 · IntroReferral
Introduced in House
2025-09-30 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.